Jump to main content
Jump to site search

All chapters
Previous chapter Next chapter

CHAPTER 1

Introduction to Antibody–Drug Conjugates (ADCs)

Antibody–drug conjugates (ADCs) are monoclonal antibodies (mAbs) or antibody fragments attached to biologically active molecules through chemical linkers with labile bonds. Currently, four ADCs have been approved by the US Food and Drug Administration (FDA): gemtuzumab ozogamicin (Mylotarg®), brentuximab vedotin (Adcetris®), ado-trastuzumab emtansine (Kadcyla®) and inotuzumab ozogamicin (Besponsa®); along with two immunotoxins [moxetumomab pasudotox (Lumoxiti®) and tagraxofusp (Elzonris®)]. This chapter reviews the basis of ADCs as anticancer therapeutics and highlights their advantages and disadvantages. Although there has been extensive research in the area of ADCs over the past few decades, there is still much that can be done to improve efficacy and reduce side effects.

Publication details

https://doi.org/10.1039/9781788012898-00001
Print publication date
15 Jul 2019
Copyright year
2019
Print ISBN
978-1-78801-077-1
PDF eISBN
978-1-78801-289-8
ePub eISBN
978-1-78801-845-6
From the book series:
Drug Discovery